SER compared with ENVB: revenue, margins and what each company keeps, and the suppliers and customers both name

SERSerina Therapeutics, Inc.

Mkt capRevenueRevenue

ENVBEnveric Biosciences, Inc.

Mkt capRevenueRevenue

Compare

SERSerina Therapeutics, Inc.

ENVBEnveric Biosciences, Inc.

Price

Mkt cap

Revenue

Earnings history

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

last 4 reports each · paired by recencyMethod ›

SER1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▼−1.75%—

ENVB1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▼−3.58%—

= impliedSER realized, solidENVB realized, hatchedOne scale, both sides: full bar = 4%× = |realized| ÷ impliedSource: market data

SERSerina Therapeutics, Inc.

1.93▲+2.12%· post 1.98

Mkt cap$31.8MRevenue$130,000Q2 FY25

ENVBEnveric Biosciences, Inc.

1.43▼−2.05%· post 1.43

ClosedOct 30 '26

Mkt cap$6.4MRevenue—

Compare

ClosedOct 30 '26

SERSerina Therapeutics, Inc.

ENVBEnveric Biosciences, Inc.

1.93▲+2.12%post 1.98

Price

1.43▼−2.05%post 1.43

$31.8M

Mkt cap

$6.4M

Q2 FY25$130,000

Revenue

—

SER1.93▲+2.12%vsENVB1.43▼−2.05%ClosedOct 30 '26